Bladder cancer is a common cancer in men and women worldwide. More than 70 percent of cases are non-muscle invasive bladder cancers, but many patients progress to muscle invasive bladder cancer or metastatic disease. To improve the prognosis of bladder cancer, employing effective methods for early detection and regular follow-up is vital for the patient.
Non-invasive bladder cancer tests have many potential applications, such as helping to diagnose recurrence, reducing the need for invasive testing, and detecting whether patients fall into a high-risk category. UBC® immunoassays are one type of non-invasive test.
About Bladder Cancer
Bladder cancer is three to four times more common in men than in women. Currently, more than 70 percent of cases are non-muscle invasive bladder cancers, but the recurrence rate is high. Therefore, many patients progress to muscle invasive bladder cancer or metastatic disease.
Cystoscopy and urine cytology are the most common methods for detection and assessment of recurrence of bladder cancer. Cystoscopy causes patients pain and discomfort, and, in cases with small tumors or carcinoma in situ, a diagnosis is not readily made. Urine cytology, a non-invasive urine test, is the standard method of detection for bladder cancer and is a recommended supplement to cystoscopy. Cytology has the advantage of high specificity, but shows low sensitivity for well-differentiated or low-grade tumors.